Myriad Genetics links up with Ciba Pharmaceuticals (US)
This article was originally published in Clinica
Myriad Genetics will retain worldwide diagnostic rights to cardiovascular genes discovered through a collaborative agreement with Ciba Pharmaceuticals (US). The $60 million, five-year agreement signed this month provides for $32 million in equity and research funding, a potential $28 million in milestone payments and future royalties. The collaboration will combine Myriad's gene technology and Ciba's pharmaceutical expertise. Ciba will receive an exclusive worldwide licence to all resulting therapeutic products.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.